Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Post by Mapleleaf57on Dec 04, 2020 6:40pm
194 Views
Post# 32042553

here is a good read .

here is a good read .

https://stockinvest.us/stock/CRDL.TO
CRDL.TO Stock Risk

This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.24 between high and low, or 9.76%. For the last week the stock has had a daily average volatility of 5.80%.

Our recommended stop-loss:We hold a sell evaluation for this stock. No stop-loss set.

Overall risk:Weaker technical forecast for Cardiol Therapeutics Inc. Class A as stock downgraded to Strong Sell Candidate. (Updated on December 03, 2020)

Sell candidate since 2020-12-02 Loss -3.47% PDF

The Cardiol Therapeutics Inc. Class A stock price fell by -3.47% on the last day (Thursday, 3rd Dec 2020) from $2.59 to $2.50. and has now fallen 3 days in a row. During the day the stock fluctuated 9.76% from a day low at $2.46 to a day high of $2.70. The price has fallen in 5 of the last 10 days and is down by -9.42% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. on the last day, the trading volume fell by -6 thousand shares and in total, 70 thousand shares were bought and sold for approximately $174.99 thousand.

Signals & Forecast

There are few to no technical positive signals at the moment. The Cardiol Therapeutics Inc. Class A stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $2.55 and $2.85. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, December 01, 2020, and so far it has fallen -7.41%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -12.77% during the next 3 months and, with a 90% probability hold a price between $1.83 and $2.78 at the end of this 3-month period.Very Low Low Medium High Very High


 

<< Previous
Bullboard Posts
Next >>